ASP-1929 Photoimmunotherapy

COMBINATION_PRODUCT5 trials

Sponsors

Rakuten Medical, Inc., Brown University

Conditions

Head and Neck CancerPancreatic Cancer BorderlinePancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical ResectionPancreatic Cancer ResectableRecurrent Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neck

Phase 1

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

Not yet recruitingNCT07698613

Brown UniversityPancreatic Cancer Borderline, Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Resectable

Start: 2026-09-01End: 2033-09-01Target: 30Updated: 2026-07-13

Phase 2

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Active, not recruitingNCT05182866

Rakuten Medical, Inc.Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck

Start: 2022-01-21End: 2026-06-30Updated: 2024-08-16

ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

TerminatedNCT05265013

Rakuten Medical, Inc.Head and Neck Cancer

Start: 2022-04-19End: 2024-03-29Updated: 2024-11-04

Phase 3

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Active, not recruitingNCT03769506

Rakuten Medical, Inc.Head and Neck Cancer

Start: 2019-05-09End: 2025-12-31Updated: 2025-01-16

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

RecruitingNCT06699212

Rakuten Medical, Inc.Recurrent Head and Neck Squamous Cell Carcinoma

Start: 2024-12-24End: 2028-09-30Target: 412Updated: 2025-10-15

Related Papers

A phase 3, randomized, double-arm, open-label, controlled study of ASP-1929 photoimmunotherapy (PIT) versus physician’s choice standard of care (SOC) for patients with locoregional, recurrent head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2026-05-27

A phase 3 randomized study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in locoregional recurrent head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2025-05-282 citations

SNAP-Tag-Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light-Accessible Melanotransferrin-Expressing Melanoma and Triple-Negative Breast Cancer.

2025-05-011 citations

Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System.

2023-02-073 citations

Phase 1/2a, open‐label, multicenter study of <scp>RM</scp>‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

Head & Neck2021-10-09156 citations

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma.

2021-06-2481 citations

Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy

EBioMedicine2021-05-011 citations

Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity

International Immunology2020-05-27128 citations

Near infrared photoimmunotherapy: a new type of immune theranostic technology for cancer

2020-04-013 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Near-Infrared Photoimmunotherapy of Cancer.

2019-07-23317 citations

A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

Journal of Clinical Oncology2019-05-2010 citations